Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Published byGustavo Rico Camacho Modified over 6 years ago

Similar presentations

Presentation on theme: "Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and."— Presentation transcript:

1 Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and b, d) small-cell lung cancer patients according to the use of thoracic radiotherapy (TRT). Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and b, d) small-cell lung cancer patients according to the use of thoracic radiotherapy (TRT). CT: chemotherapy. Arsela Prelaj et al. ERJ Open Res 2017;3: ©2017 by European Respiratory Society

Download ppt "Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and."

Similar presentations

Oncol Res Treat 2016;39: DOI: /

Oncol Res Treat 2016;39: DOI: /
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.

The 20-year overall survival was significantly higher in the newborn screening (NBS) group than in the symptoms group for each of the subgroups defined.
Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.
Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.

Flowchart for calculating the relative risk (RR) for cancer X and lung cancer (LC). Flowchart for calculating the relative risk (RR) for cancer X and lung.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.
Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.

Prevalence of true-positive, false-negative and false-positive cases of chronic obstructive pulmonary disease identified with the fixed-limit Global Initiative.
A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)
A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,

A) CT scan of patient number 1, before pembrolizumab; b) CT scan of patient number 1, after 11 pembrolizumab infusions; c) CT scan of patient number 1,
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.
Survival without tracheostomy

Survival without tracheostomy
Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer  Hidenobu Ishii, MD,
Table 2. Progression-Free Survival

Table 2. Progression-Free Survival
Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p

Influence of do-not-resuscitate (DNR) order specification on overall survival in chronic obstructive pulmonary disease (COPD) patients (log rank test p
Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.

Kaplan–Meier curve for the time until the development of lung cancer in patients with idiopathic pulmonary fibrosis. Kaplan–Meier curve for the time until.
Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.

Bland–Altman comparison of lung clearance index (LCI) from multiple breath wash-out following open and modified closed circuit wash-in for both healthy.
Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.
A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)

A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)

Similar presentations

Ads by Google